Determinants of persistence and recovery of chronic coronavirus disease 2019 chemosensory dysfunction

IF 11.2 1区 医学 Q1 ALLERGY Journal of Allergy and Clinical Immunology Pub Date : 2025-01-01 Epub Date: 2024-09-11 DOI:10.1016/j.jaci.2024.08.027
Dante G. Minichetti BA , Amelia Boyd BA , Evan Lemire MS , Jonathan Hacker BA , Adam L. Haber PhD , Rachel E. Roditi MD , Mark W. Albers MD, PhD , Stella Lee MD , Kathleen M. Buchheit MD , Tanya M. Laidlaw MD , Lora G. Bankova MD
{"title":"Determinants of persistence and recovery of chronic coronavirus disease 2019 chemosensory dysfunction","authors":"Dante G. Minichetti BA ,&nbsp;Amelia Boyd BA ,&nbsp;Evan Lemire MS ,&nbsp;Jonathan Hacker BA ,&nbsp;Adam L. Haber PhD ,&nbsp;Rachel E. Roditi MD ,&nbsp;Mark W. Albers MD, PhD ,&nbsp;Stella Lee MD ,&nbsp;Kathleen M. Buchheit MD ,&nbsp;Tanya M. Laidlaw MD ,&nbsp;Lora G. Bankova MD","doi":"10.1016/j.jaci.2024.08.027","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In 2% to 4% of patients, coronavirus disease 2019 (COVID-19) chemosensory dysfunction (CSD) persists beyond 6 months, accounting for up to 4 million people in the United States. The predictors of persistence and recovery require further exploration.</div></div><div><h3>Objective</h3><div>We sought to define the predictors of recovery and assess the quality of CSD in registry subjects with self-reported persistent smell and taste dysfunction after COVID-19.</div></div><div><h3>Methods</h3><div>COVID-19 CSD participants (n = 408) from the 4 major waves of the pandemic completed questionnaires at 4 time points between 2021 and 2023, assessing demographics, sinonasal symptoms, and self-assessed recovery. Objective measurements of smell (UPSIT) and taste (BWETT) were performed on a subcohort (n = 108).</div></div><div><h3>Results</h3><div>In this chronic CSD cohort, the average symptom duration was 24 ± 5 months, with 70% of those who contracted COVID-19 in 2020 report ongoing dysfunction. Phantosmia and dysgeusia were most prevalent in the early waves of COVID-19, while most participants reported disrupted ability to distinguish scents and flavors as well as undulating chemosensory function. Subjects reported low incidence of subjective sinonasal symptoms but high prevalence of sleep and mood disturbance. Cigarette smoke phantosmia was predictive of persistence of CSD. Conversely, self-reported environmental allergies and hypertension were predictive of recovery, and dust mite allergies specifically were negative predictors of cigarette smoke phantosmia. Finally, no treatment resolved CSD, but nasal steroids were reported to be effective by recovered CSD subjects. Objective measures of both smell and taste were significantly reduced in patients with chronic CSD compared to controls.</div></div><div><h3>Conclusions</h3><div>Chronic COVID-19 CSD is a syndrome resistant to standard anti-inflammatory therapy. Preexisting environmental allergies and hypertension predict recovery, while cigarette smoke phantosmia predicts persistence.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"155 1","pages":"Pages 120-134"},"PeriodicalIF":11.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674924009138","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

In 2% to 4% of patients, coronavirus disease 2019 (COVID-19) chemosensory dysfunction (CSD) persists beyond 6 months, accounting for up to 4 million people in the United States. The predictors of persistence and recovery require further exploration.

Objective

We sought to define the predictors of recovery and assess the quality of CSD in registry subjects with self-reported persistent smell and taste dysfunction after COVID-19.

Methods

COVID-19 CSD participants (n = 408) from the 4 major waves of the pandemic completed questionnaires at 4 time points between 2021 and 2023, assessing demographics, sinonasal symptoms, and self-assessed recovery. Objective measurements of smell (UPSIT) and taste (BWETT) were performed on a subcohort (n = 108).

Results

In this chronic CSD cohort, the average symptom duration was 24 ± 5 months, with 70% of those who contracted COVID-19 in 2020 report ongoing dysfunction. Phantosmia and dysgeusia were most prevalent in the early waves of COVID-19, while most participants reported disrupted ability to distinguish scents and flavors as well as undulating chemosensory function. Subjects reported low incidence of subjective sinonasal symptoms but high prevalence of sleep and mood disturbance. Cigarette smoke phantosmia was predictive of persistence of CSD. Conversely, self-reported environmental allergies and hypertension were predictive of recovery, and dust mite allergies specifically were negative predictors of cigarette smoke phantosmia. Finally, no treatment resolved CSD, but nasal steroids were reported to be effective by recovered CSD subjects. Objective measures of both smell and taste were significantly reduced in patients with chronic CSD compared to controls.

Conclusions

Chronic COVID-19 CSD is a syndrome resistant to standard anti-inflammatory therapy. Preexisting environmental allergies and hypertension predict recovery, while cigarette smoke phantosmia predicts persistence.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性 COVID19 化感功能障碍持续和恢复的决定因素
背景2-4%的患者的COVID19化学感觉功能障碍(CSD)会持续6个月以上,在美国多达400万人。目的在 COVID19 后自我报告持续存在嗅觉和味觉功能障碍的登记受试者中,确定恢复的预测因素并评估 CSD 的质量。方法来自四次大流行的 COVID19 CSD 参与者(n=408)在 2021 年至 2023 年期间的四个时间点填写问卷,评估人口统计学、鼻窦症状和自我评估的恢复情况。结果 在这个慢性 CSD 队列中,平均症状持续时间为 24±5 个月,但 2020 年感染 COVID19 的患者中有 70% 仍有功能障碍。幻视和味觉障碍在COVID19的早期波段最为普遍,而大多数受试者报告说,他们分辨气味和味道的能力受到了干扰,化学感觉功能也出现了起伏。受试者报告的主观鼻窦症状发生率较低,但睡眠和情绪障碍的发生率较高。香烟幻味可预测 CSD 的持续性。相反,自我报告的环境过敏则预示着疾病的康复,尤其是尘螨过敏,是香烟幻味的负面预测因素。最后,任何治疗方法都不能解决 CSD 问题,但已康复的 CSD 受试者表示鼻用类固醇有效。与对照组相比,慢性 CSD 患者嗅觉和味觉的客观指标均明显下降。已有的环境过敏和高血压预示着病情的恢复,而香烟烟雾幻嗅则预示着病情的持续。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
25.90
自引率
7.70%
发文量
1302
审稿时长
38 days
期刊介绍: The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
期刊最新文献
Reply. Etiologic diagnosis of seasonal allergic rhinitis supported by artificial intelligence: the @IT-2020 project. Molecular allergen inhibition assay for allergen extract identity, purity, and potency assessment. Incidence of Autoimmune Diseases in Children with Atopy Treated with Dupilumab. Improving clinical risk stratification in CVID: The importance of robust statistical testing and accurate event reporting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1